Potential usefulness of quinine to circumvent the anthracycline resistance in clinical practice.

Quinine, the widely used antimalaria agent, was found to increase the cytotoxicity of epideoxorubicin (epiDXR) in resistant DHD/K12 rat colon cancer cells in vitro. Quinine appeared as slightly less effective than quinidine or verapamil for anthracycline potentiation but its weaker cardiotoxicity co...

Descripción completa

Detalles Bibliográficos
Autores principales: Chauffert, B., Pelletier, H., Corda, C., Solary, E., Bedenne, L., Caillot, D., Martin, F.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1990
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971452/
https://www.ncbi.nlm.nih.gov/pubmed/2206948
_version_ 1782134913075511296
author Chauffert, B.
Pelletier, H.
Corda, C.
Solary, E.
Bedenne, L.
Caillot, D.
Martin, F.
author_facet Chauffert, B.
Pelletier, H.
Corda, C.
Solary, E.
Bedenne, L.
Caillot, D.
Martin, F.
author_sort Chauffert, B.
collection PubMed
description Quinine, the widely used antimalaria agent, was found to increase the cytotoxicity of epideoxorubicin (epiDXR) in resistant DHD/K12 rat colon cancer cells in vitro. Quinine appeared as slightly less effective than quinidine or verapamil for anthracycline potentiation but its weaker cardiotoxicity could counterbalance this disadvantage in vivo. Serum from six patients treated by conventional doses of quinine (25-30 mg kg-1 day-1) was demonstrated to enhance the accumulation of epiDXR in DHD/K12 cells as judged by fluorescence microscopy and HPLC assay (1.6 to 6-fold compared with control serum). In this patients quinine concentrations in serum ranged from 4.4 to 10.1 micrograms ml-1. Our results suggest that quinine could be safely used as anthracycline resistance modifier in clinical practice. IMAGES:
format Text
id pubmed-1971452
institution National Center for Biotechnology Information
language English
publishDate 1990
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19714522009-09-10 Potential usefulness of quinine to circumvent the anthracycline resistance in clinical practice. Chauffert, B. Pelletier, H. Corda, C. Solary, E. Bedenne, L. Caillot, D. Martin, F. Br J Cancer Research Article Quinine, the widely used antimalaria agent, was found to increase the cytotoxicity of epideoxorubicin (epiDXR) in resistant DHD/K12 rat colon cancer cells in vitro. Quinine appeared as slightly less effective than quinidine or verapamil for anthracycline potentiation but its weaker cardiotoxicity could counterbalance this disadvantage in vivo. Serum from six patients treated by conventional doses of quinine (25-30 mg kg-1 day-1) was demonstrated to enhance the accumulation of epiDXR in DHD/K12 cells as judged by fluorescence microscopy and HPLC assay (1.6 to 6-fold compared with control serum). In this patients quinine concentrations in serum ranged from 4.4 to 10.1 micrograms ml-1. Our results suggest that quinine could be safely used as anthracycline resistance modifier in clinical practice. IMAGES: Nature Publishing Group 1990-09 /pmc/articles/PMC1971452/ /pubmed/2206948 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Chauffert, B.
Pelletier, H.
Corda, C.
Solary, E.
Bedenne, L.
Caillot, D.
Martin, F.
Potential usefulness of quinine to circumvent the anthracycline resistance in clinical practice.
title Potential usefulness of quinine to circumvent the anthracycline resistance in clinical practice.
title_full Potential usefulness of quinine to circumvent the anthracycline resistance in clinical practice.
title_fullStr Potential usefulness of quinine to circumvent the anthracycline resistance in clinical practice.
title_full_unstemmed Potential usefulness of quinine to circumvent the anthracycline resistance in clinical practice.
title_short Potential usefulness of quinine to circumvent the anthracycline resistance in clinical practice.
title_sort potential usefulness of quinine to circumvent the anthracycline resistance in clinical practice.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971452/
https://www.ncbi.nlm.nih.gov/pubmed/2206948
work_keys_str_mv AT chauffertb potentialusefulnessofquininetocircumventtheanthracyclineresistanceinclinicalpractice
AT pelletierh potentialusefulnessofquininetocircumventtheanthracyclineresistanceinclinicalpractice
AT cordac potentialusefulnessofquininetocircumventtheanthracyclineresistanceinclinicalpractice
AT solarye potentialusefulnessofquininetocircumventtheanthracyclineresistanceinclinicalpractice
AT bedennel potentialusefulnessofquininetocircumventtheanthracyclineresistanceinclinicalpractice
AT caillotd potentialusefulnessofquininetocircumventtheanthracyclineresistanceinclinicalpractice
AT martinf potentialusefulnessofquininetocircumventtheanthracyclineresistanceinclinicalpractice

Ejemplares similares